Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:ACRS's Cash-to-Debt is ranked higher than
65% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. NAS:ACRS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ACRS' s Cash-to-Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Interest Coverage No Debt
NAS:ACRS's Interest Coverage is ranked higher than
53% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:ACRS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:ACRS' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Altman Z-Score: 71.64
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -40.73
NAS:ACRS's ROE % is ranked lower than
57% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. NAS:ACRS: -40.73 )
Ranked among companies with meaningful ROE % only.
NAS:ACRS' s ROE % Range Over the Past 10 Years
Min: -64.46  Med: -50.58 Max: -36.7
Current: -40.73
-64.46
-36.7
ROA % -38.91
NAS:ACRS's ROA % is ranked lower than
62% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. NAS:ACRS: -38.91 )
Ranked among companies with meaningful ROA % only.
NAS:ACRS' s ROA % Range Over the Past 10 Years
Min: -53.93  Med: -36.88 Max: -35.59
Current: -38.91
-53.93
-35.59
ROC (Joel Greenblatt) % -9675.47
NAS:ACRS's ROC (Joel Greenblatt) % is ranked lower than
88% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. NAS:ACRS: -9675.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ACRS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -27668.42  Med: -7273.25 Max: -3195.88
Current: -9675.47
-27668.42
-3195.88
GuruFocus has detected 1 Warning Sign with Aclaris Therapeutics Inc $NAS:ACRS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ACRS's 30-Y Financials

Financials (Next Earnings Date: 2017-08-11 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

ACRS Guru Trades in

ACRS Guru Trades in

Q4 2016

ACRS Guru Trades in Q4 2016

Jim Simons 174,600 sh (New)
» More
Q1 2017

ACRS Guru Trades in Q1 2017

Louis Moore Bacon 62,500 sh (New)
Steven Cohen 459,916 sh (New)
Jim Simons 88,079 sh (-49.55%)
» More
» Details

Insider Trades

Latest Guru Trades with ACRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:AMAG, NAS:KERX, NAS:CYTK, NAS:ANIK, OTCPK:IPHYF, NAS:BYSI, NAS:VNDA, NAS:MGNX, NAS:ADRO, NYSE:MYOV, NAS:JNCE, NAS:RVNC, NAS:OMER, NAS:CRSP, NAS:ENTA, NAS:MESO, NAS:ACOR, NAS:AUPH, NAS:PRTK, NAS:EDIT » details
Traded in other countries:8AT.Germany,
Headquarter Location:USA
Aclaris Therapeutics Inc is a biotechnology company focused on identifying, developing and commercializing differentiated drugs to address unmet needs in dermatology.

Aclaris Therapeutics Inc was incorporated in Delaware in July 2012. The Company is a clinical stage pharmaceutical company. It is engaged in identifying, developing and commercializing differentiated topical drugs to address unmet needs in dermatology. Its product includes A-101, a proprietary topical solution for treatment of seborrheic keratosis, or SK, a common non-malignant skin tumor. It faces competition from pharmaceutical and specialty pharmaceutical companies, academic institutions and governmental agencies and public & private research institutions. The Company is subject to governmental rules & regulations.

Top Ranked Articles about Aclaris Therapeutics Inc

Aclaris Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017
Aclaris Therapeutics Reports First Quarter 2017 Financial Results
FDA Accepts Aclaris Therapeutics’ New Drug Application for Topical Treatment of Seborrheic Keratosis, a Common Skin Condition
Aclaris Therapeutics Completes Phase 1 Clinical Trial of ATI-50001 for the Treatment of Alopecia Universalis and Alopecia Totalis
Aclaris Therapeutics to Attend Upcoming Investor Conferences
Aclaris Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017
Aclaris Therapeutics Announces Notice of Allowance for a U.S. Patent Application Covering Lead Candidate A-101 Topical Solution
Aclaris Therapeutics Hosts Symposium on JAK Inhibitors at the 76th Annual Society for Investigative Dermatology Meeting
Aclaris Therapeutics Announces Notice of Allowance for Two U.S. Patent Applications Covering Baricitnib and Decernotinib, Respectively, for Hair Loss Disorders
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

--  Provides Update on Clinical and Other Developments 
--  Initiates Financial Guidance for Full Year 2017 
--  Management to Host Conference Call at 8:00 a.m. ET today MALVERN, Pa., March 15, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biotechnology company, today announced financial results for the fourth quarter and year ended December 31, 2016 and provided an update on its clinical development programs.    “The year was a transformational year as we continued to make progress toward our goal of becoming a fully integrated biotechnology company.  In November 2016, we reported that two pivotal Phase 3 trials of our lead product candidate A-101 40% Topical Solution met all primary and secondary endpoints of each trial, achieving clinically and statistically significant clearance of seborrheic keratosis (SK) lesions.  In February 2017, we submitted a New Drug Application (NDA) for A-101 40% Topical Solution for the treatment of SK to the U.S. Food and Drug Administration (FDA),” said Dr. Neal Walker, President and Chief Executive Officer of Aclaris.  “During 2016 we also reported positive data from a Phase 2 trial of A-101 45% Topical Solution for the treatment of common warts.  Finally, we recently completed a Phase 1 clinical trial of ATI-50001, our investigational Janus Kinase (JAK) inhibitor, for the treatment of alopecia totalis and alopecia universalis.” Clinical Pipeline Update A-101 40% Topical Solution In November 2016, reported positive data from two pivotal Phase 3 trials, SEBK-301 and SEBK-302, in which A-101 40% Topical Solution achieved statistically significant and clinically meaningful results on all primary and secondary endpoints.  SEBK-301 and SEBK-302 enrolled 937 patients in total and were conducted at 34 investigational centers in the United States.There were no treatment-related serious adverse events among patients treated with A-101 40% Topical Solution, and local skin reactions (LSR), if present, were predominantly classified as mild.  The rates of hypopigmentation, hyperpigmentation, and scarring classified as greater than mild were less than one percent in all groups in both trialsIn February 2017, submitted an NDA to the FDA for A-101 40% Topical Solution as a treatment for SK.  Plan to submit a marketing authorization application (MAA) for A-101 40% Topical Solution in the European Union in the second half of 2017. A-101 45% Topical Solution In August 2016, reported positive data from a Phase 2 trial, WART-201, in which A-101 45% Topical Solution achieved statistically significant and clinically meaningful results on all primary and secondary endpoints.  WART-201 enrolled 98 patients in total and was conducted at six investigational centers in the United States.A-101 45% Topical Solution was well-tolerated and LSRs were primarily mild in severity and similar to placebo. The most frequently reported LSR across treatment groups was mild erythema.Completed an FDA teleconference and plan to initiate two Phase 2 clinical trials of A-101 45% Topical Solution for the treatment of warts in mid-2017. JAK Inhibitor In October 2016, we submitted an Investigational New Drug Application (IND) to the FDA for ATI-50001 for the treatment of alopecia totalis and alopecia universalis and recently completed a Phase 1 clinical trial.Plan to initiate a Phase 2 dose ranging trial with ATI-50001 for the oral treatment of alopecia totalis and alopecia universalis in the second half of 2017.Plan to submit IND for ATI-50002 for the topical treatment of patchy alopecia areata mid-2017.Plan to initiate a Phase 2 dose ranging trial with ATI-50002 for the topical treatment of patchy alopecia areata in the second half of 2017.Aclaris has exclusively licensed several patents and patent applications involving novel selective JAK 1/3 inhibitors, including a patent portfolio from Rigel Pharmaceuticals, Inc. that covers ATI-50001 as well as ATI-50002, a topical formulation also being developed as a potential treatment for alopecia areata.  In addition, Aclaris has exclusively licensed a patent portfolio from JAKPharm and Key Organics directed to novel covalently binding, highly selective JAK 3 inhibitors.  Finally, Aclaris has exclusively licensed a patent portfolio from Columbia University directed to methods of using JAK inhibitors for the treatment of alopecia areata, androgenetic alopecia, and other dermatological conditions.  This portfolio includes a recently issued U.S. patent directed to methods of treating alopecia areata, androgenetic alopecia and other hair loss disorders by administering ruxolitinib, and a recently issued patent in Japan directed to pharmaceutical compositions comprising ruxolitinib, baricitinib or other JAK inhibitors for use in treating alopecia areata, androgenetic alopecia and other hair loss disorders. Business Highlights and Recent Developments During 2016, raised approximately $117 million in net proceeds from the sale of our common stock.Continued to build out research and development and commercial infrastructure.Appointed Andrew Powell to the Board of Directors – Andrew has more than 27 of experience years in the biotechnology and pharmaceutical industry.  He most recently served as Senior Vice President, General Counsel and Corporate Secretary of Medivation, Inc. from May 2015 until its acquisition by Pfizer, Inc. in November 2016. Prior to Medivation, Mr. Powell served in executive leadership roles at InterMune, Inc., where he played a leadership role in InterMune’s acquisition by Roche Holdings AG, ImClone Systems, Inc., where he helped the company grow before playing a key role in its sale to Eli Lilly, Collagenex Pharmaceuticals, Inc., where he was part of a senior team that repositioned the company as a leader in dermatology before its acquisition by Galderma Pharma S.A., and Baxter International, Inc.,  where he was instrumental in a series of transactions that established Baxter throughout Asia.Appointed Bill Humphries to the Board of Directors – Bill is the Executive Vice President, Group Chairman Dermatology of Valeant Pharmaceuticals.  Previously, Bill was President and Chief Executive Officer of Merz, Inc. (affiliate of Merz Pharma Group), North American business and was a member of the Merz Pharma Board and the Chairman of the Merz, Inc. Board of Directors.  At Merz, Inc., Bill was responsible for the continued and accelerated growth of the Aesthetics, Dermatology, OTC/OTX and Neuroscience businesses within North America. Bill has more than 29 years of experience in the specialty pharmaceutical industry, with more than 26 of those years focused on the commercialization of products in medical dermatology and aesthetics. 2017 Financial Outlook Aclaris estimates net cash burn for 2017 to be in the range of $65 million to $70 million not including financing activities and potential acquisitions of complementary businesses or technologies.
 Aclaris estimates 2017 total operating expenses to be in the range of $84 million to $92 million, or $70 million to $75 million when excluding estimated stock-based compensation expense of $14 million to $17 million.
 Aclaris anticipates 2017 research and development expenses to be in the range of $51 million to $58 million, or $46 million to $52 million when excluding estimated stock-based compensation expense of $5 million to $6 million. Financial Highlights Liquidity and Capital Resources As of December 31, 2016, Aclaris had aggregate cash, cash equivalents and marketable securities of $174.1 million, compared to $92.0 million as of December 31, 2015.  The $82.1 million increase during the year ended December 31, 2016 included: 

Net cash from financing activities of $18.5 million in net proceeds received from a private placement financing completed in June 2016 and $98.2 million in net proceeds received from a follow-on offering completed in November 2016.

Net cash used in operations of $34.6 million during the year ended December 31, 2016. This amount was composed of a net loss of $48.1 million, less non-cash operating expenses of $2.8 million for the acquisition of Vixen Pharmaceuticals, Inc., and $6.1 million in stock-based compensation expense, as well as $4.5 million in net cash increases in working capital. 

Aclaris presently anticipates that its cash, cash equivalents and marketable securities as of December 31, 2016 will be sufficient to fund its operations through at least the end of 2018, without giving effect to potential new business development transactions or financing activities. Fourth Quarter 2016 Financial Results Net loss attributable to common stockholders was $11.5 million for the fourth quarter of 2016, compared to $4.9 million for the fourth quarter of 2015. 

Total operating expenses for the fourth quarter of 2016 were $11.6 million, compared to $4.8 million for the fourth quarter of 2015.

Research and development expenses were $6.9 million for the fourth quarter of 2016, compared to $2.4 million for the fourth quarter of 2015. The increase of $4.5 million was primarily due to a $2.2 million increase in direct costs associated with the preclinical development expenses related to the JAK inhibitor technology, a $1.4 million increase in the clinical development of A-101, and a $1.1 million increase in personnel-related expenses, including stock-based compensation, due to increased headcount.

General and administrative expenses were $4.7 million for the fourth quarter of 2016, compared to $2.4 million for the fourth quarter of 2015. The increase of $2.3 million was primarily attributable to increases of $1.4 million in personnel-related expenses, including stock-based compensation, due to increased headcount, and $0.8 million in market research costs related to pre-commercial activities for A-101 40% Topical Solution.  Full Year 2016 Financial Results Net loss attributable to common stockholders was $48.1 million for the year ended December 31, 2016, compared to $23.1 million for the year ended December 31, 2015.

Total operating expenses were $48.6 million for the year ended December 31, 2016, compared to $20.7 million for the year ended December 31, 2015.
  Research and development expenses were $33.5 million for the year ended December 31, 2016, compared to $15.3 million for the prior year. The increase of $18.2 million was primarily due to a $7.3 million increase in direct costs associated with the preclinical development expenses related to the JAK inhibitor technology, a $10.8 million increase in the clinical development of A-101, and a $4.2 million increase in personnel-related expenses, including stock-based compensation, due to increased headcount.  The increases noted above were partially offset by a decrease of $4.6 million in licensing expenses as Aclaris incurred $3.4 million of expenses associated with the Vixen acquisition in the year ended December 31, 2016, compared to $8.0 million of expenses for the upfront payment made to a third party during the year ended December 31, 2015. 

General and administrative expenses were $15.1 million for the year ended December 31, 2016, compared to $5.3 million for the prior year. The increase of $9.8 million was primarily attributable to increases of $5.4 million in personnel-related expenses, including stock-based compensation, due to increased headcount, $1.5 million in professional fees associated with being a public company, and $1.5 million in market research costs related to pre-commercial activities for A-101 40% Topical Solution. Company to Host Conference Call
Management will conduct a conference call at 8:00 a.m. ET today to discuss Aclaris’ financial results and provide a general business update.  The conference will be webcast live over the Internet and can be accessed by logging on to the “Investors” page of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event.  A replay of the webcast will be archived on the Aclaris Therapeutics website for 30 days following the call.  To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference conference ID 62366728 prior to the start of the call.  About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology.  Aclaris is based in Malvern, Pennsylvania. Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan," "potential," "will," and similar expressions, and are based on Aclaris' current beliefs and expectations. These forward-looking statements include expectations regarding Aclaris’ use of cash and research and development and total operating expenses during 2017, development programs in skin and hair conditions, and the clinical development of JAK inhibitors. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris' reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of Aclaris' Annual Report on Form 10-K for the year ended December 31, 2016 and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the "Financial Information" section of the Investors page of Aclaris' website at http://www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
 Aclaris Therapeutics, Inc.Consolidated Statements of Operations(in thousands, except share and per share data)   Three Months Ended Year Ended  December 31, December 31,   2016   2015   2016   2015 Revenue $-  $-  $-  $- Operating expenses:        Research and development (1)  6,943   2,402   33,476   15,339 General and administrative (1)  4,684   2,400   15,091   5,328 Total operating expenses  11,627   4,802   48,567   20,667 Loss from operations  (11,627)  (4,802)  (48,567)  (20,667)Other income, net  152   88   488   104          Net loss  (11,475)  (4,714)  (48,079)  (20,563)Accretion of convertible preferred stock  â€‘   (213)  -   (2,566)Net loss attributable to common stockholders $(11,475) $(4,927) $(48,079) $(23,129)Net loss per share attributable to common stockholders, basic and diluted $(0.49) $(0.28) $(2.25) $(3.79)Weighted average common shares outstanding, basic and diluted  23,390,746   17,832,264   21,415,733   6,107,042                 (1) Amounts include stock-based compensation expense as follows:               Research and development$714  $183  $2,291  $257 General and administrative 1,196   464   3,813   634 Total stock-based compensation expense$1,910  $647  $6,104  $891         
Aclaris Therapeutics, Inc. Selected Consolidated Balance Sheet Data (in thousands)     December 31, 2016 December 31, 2015         Cash, cash equivalents and investments $174,134 $92,038 Total assets  176,085  94,076 Total current liabilities  6,223  1,555 Total liabilities  6,595  1,555 Total stockholders' equity  169,490  92,521 
 

Contact:

Aclaris Contact
Michael Tung, M.D.
Vice President / Investor Relations
484-329-2140
[email protected]

Media Contact
Mariann Caprino
TogoRun
917-242-1087
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 4.03
ACRS's PB Ratio is ranked lower than
58% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. ACRS: 4.03 )
Ranked among companies with meaningful PB Ratio only.
ACRS' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 8.29
Current: 4.03
0
8.29
EV-to-EBIT -10.55
ACRS's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. ACRS: -10.55 )
Ranked among companies with meaningful EV-to-EBIT only.
ACRS' s EV-to-EBIT Range Over the Past 10 Years
Min: -17.53  Med: 0 Max: 0
Current: -10.55
-17.53
0
EV-to-EBITDA -10.58
ACRS's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. ACRS: -10.58 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACRS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.58  Med: 0 Max: 0
Current: -10.58
-17.58
0
Current Ratio 27.91
ACRS's Current Ratio is ranked higher than
94% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. ACRS: 27.91 )
Ranked among companies with meaningful Current Ratio only.
ACRS' s Current Ratio Range Over the Past 10 Years
Min: 7.33  Med: 20.75 Max: 55.64
Current: 27.91
7.33
55.64
Quick Ratio 27.91
ACRS's Quick Ratio is ranked higher than
94% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. ACRS: 27.91 )
Ranked among companies with meaningful Quick Ratio only.
ACRS' s Quick Ratio Range Over the Past 10 Years
Min: 7.33  Med: 20.75 Max: 55.64
Current: 27.91
7.33
55.64

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 4.38
ACRS's Price-to-Net-Cash is ranked higher than
54% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. ACRS: 4.38 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ACRS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 4.35  Med: 5.35 Max: 6.94
Current: 4.38
4.35
6.94
Price-to-Net-Current-Asset-Value 4.27
ACRS's Price-to-Net-Current-Asset-Value is ranked higher than
51% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. ACRS: 4.27 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ACRS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.23  Med: 5.25 Max: 6.81
Current: 4.27
4.23
6.81
Price-to-Tangible-Book 4.03
ACRS's Price-to-Tangible-Book is ranked higher than
50% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. ACRS: 4.03 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ACRS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4  Med: 4.72 Max: 6.76
Current: 4.03
4
6.76
Earnings Yield (Greenblatt) % -9.52
ACRS's Earnings Yield (Greenblatt) % is ranked lower than
53% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. ACRS: -9.52 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACRS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -9.64  Med: 0 Max: 348.19
Current: -9.52
-9.64
348.19

More Statistics

EPS (TTM) $ -2.09
Short Percentage of Float12.27%
52-Week Range $17.10 - 33.25
Shares Outstanding (Mil)26.73
» More Articles for NAS:ACRS

Headlines

Articles On GuruFocus.com
Aclaris Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017 May 09 2017 
Aclaris Therapeutics Reports First Quarter 2017 Financial Results May 09 2017 
FDA Accepts Aclaris Therapeutics’ New Drug Application for Topical Treatment of Seborrheic Kera May 09 2017 
Aclaris Therapeutics Completes Phase 1 Clinical Trial of ATI-50001 for the Treatment of Alopecia Uni May 05 2017 
Aclaris Therapeutics to Attend Upcoming Investor Conferences May 01 2017 
Aclaris Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017 May 01 2017 
Aclaris Therapeutics Announces Notice of Allowance for a U.S. Patent Application Covering Lead Candi Apr 26 2017 
Aclaris Therapeutics Hosts Symposium on JAK Inhibitors at the 76th Annual Society for Investigative Apr 24 2017 
Aclaris Therapeutics Announces Notice of Allowance for Two U.S. Patent Applications Covering Baricit Apr 04 2017 
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corpor Mar 15 2017 

More From Other Websites
Aclaris reports 1Q loss May 09 2017
Aclaris Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017 May 09 2017
FDA Accepts Aclaris Therapeutics’ New Drug Application for Topical Treatment of Seborrheic... May 09 2017
Aclaris Therapeutics Reports First Quarter 2017 Financial Results May 09 2017
Investor Network: Aclaris Therapeutics, Inc. to Host Earnings Call May 09 2017
Aclaris Therapeutics Completes Phase 1 Clinical Trial of ATI-50001 for the Treatment of Alopecia... May 05 2017
Aclaris Therapeutics to Attend Upcoming Investor Conferences May 01 2017
Aclaris Therapeutics Announces Notice of Allowance for a U.S. Patent Application Covering Lead... Apr 26 2017
Aclaris Therapeutics Hosts Symposium on JAK Inhibitors at the 76th Annual Society for Investigative... Apr 24 2017
Aclaris Therapeutics Announces Notice of Allowance for Two U.S. Patent Applications Covering... Apr 04 2017
Edited Transcript of ACRS earnings conference call or presentation 15-Mar-17 12:00pm GMT Mar 15 2017
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides... Mar 15 2017
Aclaris Therapeutics Submits New Drug Application for A-101 as a Novel Treatment for Seborrheic... Feb 27 2017
Aclaris Therapeutics (ACRS) Worth a Look: Stock Rises 8.5% Feb 24 2017
Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2016 Financial Results on March 15,... Feb 23 2017
Skin Lesion Drug Only Scratches the Surface, Says Aclaris CEO Feb 06 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat